Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics cash
Cash and short-term investments held at the end of each period.
Tango Therapeutics's cash was $1.00B at Jun 30, 2026. For fiscal 2025 it was $343.10M, up 33.0% from the year before. The highest annual figure on record is $485.26M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.10M | +33.0% |
| FY2024 | Dec 31, 2024 | $257.90M | -23.4% |
| FY2023 | Dec 31, 2023 | $336.89M | -8.0% |
| FY2022 | Dec 31, 2022 | $366.13M | -24.5% |
| FY2021 | Dec 31, 2021 | $485.26M | +155.0% |
| FY2020 | Dec 31, 2020 | $190.32M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.00B | +453.1% |
| Q1 FY2026 | Mar 31, 2026 | $379.80M | +75.3% |
| Q4 FY2025 | Dec 31, 2025 | $343.10M | +33.0% |
| Q3 FY2025 | Sep 30, 2025 | $152.80M | -47.9% |
| Q2 FY2025 | Jun 30, 2025 | $180.80M | -43.9% |
| Q1 FY2025 | Mar 31, 2025 | $216.70M | -36.9% |
| Q4 FY2024 | Dec 31, 2024 | $257.90M | -23.4% |
| Q3 FY2024 | Sep 30, 2024 | $293.28M | -18.5% |
| Q2 FY2024 | Jun 30, 2024 | $322.11M | +3.7% |
| Q1 FY2024 | Mar 31, 2024 | $343.60M | +3.0% |
| Q4 FY2023 | Dec 31, 2023 | $336.89M | -8.0% |
| Q3 FY2023 | Sep 30, 2023 | $359.88M | -8.5% |
| Q2 FY2023 | Jun 30, 2023 | $310.65M | -25.4% |
| Q1 FY2023 | Mar 31, 2023 | $333.64M | -25.8% |
| Q4 FY2022 | Dec 31, 2022 | $366.13M | -24.5% |
| Q3 FY2022 | Sep 30, 2022 | $393.29M | -21.9% |
| Q2 FY2022 | Jun 30, 2022 | $416.36M | +71323.7% |
| Q1 FY2022 | Mar 31, 2022 | $449.89M | +35649.0% |
| Q4 FY2021 | Dec 31, 2021 | $485.26M | +155.0% |
| Q3 FY2021 | Sep 30, 2021 | $503.81M | +32356.9% |
| Q2 FY2021 | Jun 30, 2021 | $582.94K | +2232.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.26M | – |
| Q4 FY2020 | Dec 31, 2020 | $190.32M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.55M | – |
| Q2 FY2020 | Jun 30, 2020 | $24.99K | – |
See a number that looks wrong?